As of Friday close, Moderna Inc.’s (NASDAQ:MRNA) stock was down -$0.24, moving down -0.24 percent to $99.99. The average number of shares traded per day over the past five days has been 4,005,020 shares. 1 time new highs have been achieved over the past 5 days, with a -$14.60 fall in that time frame. In the last twenty days, the average volume was 3,760,875, while in the previous 50 days, it was 4,078,968.
Since last month, MRNA stock retreated -13.40%. Shares of the company fell to $98.51 on 09/22/23, the lowest level in the past month. A 52-week high of $217.25 was reached on 01/18/23 after having rallying from a 52-week low of $95.02. Since the beginning of this year, MRNA’s stock price has dropped by -44.33% or -$79.63, and marked a new high 6 times. However, the stock has declined by -53.97% since its 52-week high.
MRNA stock investors should be aware that Moderna Inc. (MRNA) stock had its last reported insider trading activity 3 days ago on Sep 20. AFEYAN NOUBAR, the Director of the company, disposed of 15,000 shares for $104.74 on Sep 20. It resulted in a $1,571,090 divestment by the insider. Hoge Stephen sold 15,000 shares at an average price of $112.99 on Sep 15. The insider now owns 1,574,187 shares following the transaction. On Sep 13, Director AFEYAN NOUBAR sold 15,000 shares at $109.70 apiece. The transaction was valued at $1,645,522.
Valuation Metrics
Right now, Moderna Inc. (MRNA) has a P/E ratio of about 36.98. The stock’s beta is 1.65. Besides these, the trailing price-to-sales (P/S) ratio of 3.52, the price-to-book (PB) ratio of 2.25.
Financial Health
In the three months ended June 30, Moderna Inc.’s quick ratio stood at 3.20, while its current ratio was 3.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 30 was 0.05, and the total debt-to-equity ratio was 0.06. On the profitability front, the trailing twelve-month gross margin is 57.40% percent. In the year ended June 30, EBITDA margin amounted to 50.31%, whereas operating margins totaled 4.80%. Based on annual data, MRNA earned $13.85 billion in gross profit and brought in $19.26 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 40.60%. Return on equity (ROE) for the past 12 months was 6.60%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MRNA’s revenue fell -1280.52% to $1.86 billion during the quarter, while net income inched up to $344.0 million. While analysts expected Moderna Inc. to report -$4.04 quarterly earnings, the actual figure was -$3.62 per share, beating the consensus estimate by 10.40%. During the quarter, the company generated -$1.79 billion in EBITDA. The liabilities of Moderna Inc. were 4.93 billion at the end of its most recent quarter ended June 30, and its total debt was $1.17 billion. The value of shareholders’ equity is $380.59 million.
Technical Picture
This quick technical analysis looks at Moderna Inc.’s (MRNA) price momentum. With a historical volatility rate of 62.61%, the RSI 9-day stood at 34.70% on 22 September.
With respect to its five-day moving average, the current Moderna Inc. price is down by -12.74% percent or -$14.60. At present, MRNA shares trade -11.24% below its 20-day simple moving average and -25.04% percent below its 100-day simple moving average. However, the stock is currently trading approximately -21.03% below its SMA50 and -43.16% below its SMA200.
Stochastic coefficient K was 7.09% and Stochastic coefficient D was 12.18%, while ATR was 4.72. Given the Stochastic reading of 8.84% for the 14-day period, the RSI (14) reading has been calculated as 38.36%. As of today, the MACD Oscillator reading stands at -4.96, while the 14-day reading stands at -5.55.
Analyst Ratings
Moderna Inc. downgraded its rating on Moderna Inc. (NASDAQ: MRNA) to a Market perform in a note to investors on August 04, 2023. The analysts firm previously had an Outperform rating on the stock.Moderna Inc. (MRNA) has been rated Overweight by analysts. According to 2 brokerage firms, MRNA is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Moderna Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $167.00, the current consensus forecast for the stock is $66.00 – $430.00. Based on these forecasts, analysts predict Moderna Inc. (MRNA) will achieve an average price target of $179.31.
